Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial
Neuropsychiatric Disease and Treatment, 04/22/2011
Bachinskaya N et al. – Treatment with EGb 761, at a once–daily dose of 240 mg, was safe, effectively alleviated behavioral and neuropsychiatric symptoms in patients with mild to moderate dementia, and improved the wellbeing of their caregivers.
Randomized, controlled, double-blind, multicenter clinical trial involving 410 outpatients with mild to moderate dementia (Alzheimer’s disease with or without cerebrovascular disease, vascular dementia), scoring at least 5 on the Neuropsychiatric Inventory (NPI), with at least one item score of 3 or more.
Total scores on the SKT cognitive test battery (Erzigkeit’s short syndrome test) were between 9 and 23.
After random allocation, the patients took 240 mg of EGb 761 or placebo once daily for a period of 24 weeks.
Changes from baseline to week 24 in the NPI composite and in the SKT total score were the primary outcomes.
NPI distress score was chosen as a secondary outcome measure to evaluate caregivers’ distress.
NPI composite score improved by -3.2 (95% confidence interval -4.0 to -2.3) in patients taking EGb 761 (n = 202), but did not change (-0.9; 0.9) in those receiving placebo (n = 202), which resulted in a statistically significant difference in favor of EGb 761 (P < 0.001).
Treatment with EGb 761 was significantly superior to placebo for the symptoms apathy/indifference, sleep/night-time behavior, irritability/lability, depression/dysphoria, and aberrant motor behavior.
Caregivers’ distress evaluation revealed similar baseline pattern and improvements.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.